Home › Burkitt Lymphoma
Burkitt Lymphoma clinical trials recruiting in the U.S.
64 studies for Burkitt Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX20 studies
- Milwaukee, WI16 studies
- Chicago, IL15 studies
- Philadelphia, PA15 studies
- Seattle, WA14 studies
- Atlanta, GA13 studies
- New York City, NY13 studies
- Cincinnati, OH13 studies
- Los Angeles, CA10 studies
- Baldwin Park, CA10 studies
- Aurora, CO10 studies
- Durham, NC10 studies
- Kansas City, MO10 studies
- Minneapolis, MN9 studies
- Orange, CA9 studies
- Washington, DC9 studies
- Ann Arbor, MI8 studies
- Baltimore, MD8 studies
- Boston, MA8 studies
- San Francisco, CA8 studies
- Portland, OR8 studies
- Columbus, OH8 studies
- Tampa, FL7 studies
- Richmond, VA7 studies
- Mountain View, CA7 studies
- Nashville, TN7 studies
- Salt Lake City, UT7 studies
- Dallas, TX7 studies
- Providence, RI7 studies
- Jacksonville, FL7 studies
- Cleveland, OH7 studies
- Greenburgh, NY7 studies
- Grand Rapids, MI7 studies
- Oklahoma City, OK7 studies
- Birmingham, AL7 studies
- Buffalo, NY7 studies
- Clifton, NJ7 studies
- Cedar Rapids, IA6 studies
- San Antonio, TX6 studies
- Oakland, CA6 studies
By state
- Alabama7 studies
- Alaska3 studies
- Arizona7 studies
- Arkansas5 studies
- California21 studies
- Colorado13 studies
- Connecticut7 studies
- Delaware7 studies
- District of Columbia5 studies
- Florida16 studies
- Georgia13 studies
- Hawaii5 studies
- Idaho6 studies
- Illinois15 studies
- Indiana6 studies
- Iowa8 studies
- Kansas6 studies
- Kentucky5 studies
- Louisiana4 studies
- Maine4 studies
- Maryland11 studies
- Massachusetts8 studies
- Michigan10 studies
- Minnesota10 studies
- Mississippi4 studies
- Missouri8 studies
- Nebraska5 studies
- Nevada4 studies
- New Hampshire4 studies
- New Jersey8 studies
- New Mexico3 studies
- New York19 studies
- North Carolina13 studies
- North Dakota5 studies
- Ohio18 studies
- Oklahoma7 studies
- Oregon8 studies
- Pennsylvania17 studies
- Rhode Island7 studies
- South Carolina5 studies
- South Dakota5 studies
- Tennessee10 studies
- Texas23 studies
- Utah7 studies
- Vermont3 studies
- Virginia7 studies
- Washington14 studies
- Wisconsin16 studies
Recently updated studies
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Nov 13, 2026 · NCT07109219A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RecruitingPhase 1
Ages 0 to 18 · All sexes · Updated Nov 13, 2026 · NCT06173518Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07758673Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07936266Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Nov 12, 2026 · NCT03223610A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Nov 12, 2026 · NCT04546399A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
RecruitingPhase 3
Ages 1 and older · All sexes · Updated Nov 12, 2026 · NCT07223021Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Nov 3, 2026 · NCT03150693Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
RecruitingObservational study
Ages 1 to 23 · All sexes · Updated Oct 28, 2026 · NCT07422337Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 27, 2026 · NCT06124157CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RecruitingPhase 1/2
Ages 3 to 39 · All sexes · Updated Oct 26, 2026 · NCT05442515Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04545762Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RecruitingPhase 2
Ages 3 to 31 · All sexes · Updated Oct 23, 2026 · NCT02393157Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT07097363Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
RecruitingPhase 1
Ages 12 to 55 · All sexes · Updated Oct 16, 2026 · NCT07133997Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07532525Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07069699AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 13, 2026 · NCT06137118From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.